Journal
CELL REPORTS
Volume 37, Issue 1, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2021.109784
Keywords
-
Categories
Funding
- Vanderbilt Ingram Cancer Center [P30 CA68485]
- Vanderbilt Digestive Disease Research Center [DK058404]
- National Center for Advancing Translational Science (NCATS) Clinical Translational Science Award (CTSA) Program [5ULITR002243-03]
- CTSA [5UL1 RR024975-03]
- Vanderbilt-Ingram Cancer Center [P30 CA68485]
- Vanderbilt Vision Center [P30 EY08126]
- NIH/NCRR [G20 RR030956]
- NIAID/NIH [R01AI131722-S1, R01 AI157155, R01 AI127521, T32 AI095202]
- DARPA [HR0011-18-2-0001, 75N93019C00073]
- Hays Foundation COVID-19 Research Fund
- VICTR Award [VR54494]
- Dolly Parton COVID-19 Research Fund at Vanderbilt
- Welch Foundation [F-0003-19620604]
- Mercatus Center
- George Mason University
- Merck KGaA
- University of Texas College of Natural Sciences
- Cancer Prevention and Research Institute of Texas (CPRIT) [RR160023]
- HHSN [75N93019C00074]
- Fast Grants
Ask authors/readers for more resources
The emergence of SARS-CoV-2 lineages with increased transmissibility and resistance to antibody therapies poses a challenge to COVID-19 treatment. A panel of antibodies, with 54042-4 showing potent neutralization against SARS-CoV-2, including variants of concern, has been isolated using LIBRA-seq technology. The unique genetic and structural characteristics of 54042-4 make it a promising candidate for combating current and future SARS-CoV-2 variants.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages that are more transmissible and resistant to currently approved antibody therapies poses a considerable challenge to the clinical treatment of coronavirus disease (COVID-19). Therefore, the need for ongoing discovery efforts to identify broadly reactive monoclonal antibodies to SARS-CoV-2 is of utmost importance. Here, we report a panel of SARS-CoV-2 antibodies isolated using the linking B cell receptor to antigen specificity through sequencing (LIBRA-seq) technology from an individual who recovered from COVID-19. Of these antibodies, 54042- 4 shows potent neutralization against authentic SARS-CoV-2 viruses, including variants of concern (VOCs). A cryoelectron microscopy (cryo-EM) structure of 54042-4 in complex with the SARS-CoV-2 spike reveals an epitope composed of residues that are highly conserved in currently circulating SARS-CoV-2 lineages. Further, 54042-4 possesses uncommon genetic and structural characteristics that distinguish it from other potently neutralizing SARS-CoV-2 antibodies. Together, these findings provide motivation for the development of 54042-4 as a lead candidate to counteract current and future SARS-CoV-2 VOCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available